Preview

Стационарозамещающие технологии: Амбулаторная хирургия

Расширенный поиск

Выбор антикоагулянта у пациента с венозными тромбоэмболическими осложнениями

Полный текст:

Аннотация

В статье рассматриваются основные критерии выбора антикоагулянтной терапии у пациентов с венозными тромбоэмболическими осложнениями (ВТЭО) при различных клинических обстоятельствах. Приводимые данные основаны на российских и зарубежных рекомендациях по лечению и вторичной профилактике данной патологии, а также собственном опыте Пироговского центра. Особый акцент сделан на возможности амбулаторного ведения отдельных подгрупп пациентов с ВТЭО.

Об авторах

Ю. М. Стойко
ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова»
Россия


Е. Д. Карташева
ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова»
Россия


Список литературы

1. ESC Guidelines on the diagnosis and management of acute pul-mobary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Heart Journal, 2014, 35: 3033-3080.

2. Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med, 2003, 14(163): 17111717.

3. Vandy FC, Wakefield TW. Acute deep venous thrombosis. Pathophysiology and natural history. Ruterford's Vascular surgery, 2010, 1: 736-754.

4. Allison E. Burnett, Charles E. Mahan, Sara R. Vazquez, Lynn B. Oertel, David A. Garcia, Jack Ansel. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis, 2016, 41: 206-232.

5. Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol, 2004, 9(93): 1197-1199.

6. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Ассоциация флебологов России, Ассоциация сердечно-сосудистых хирургов России, Всероссийское общество хирургов, Российское научное общество терапевтов, Общество специалистов по неотложной кардиологии. Флебология, 2015, 9(2): 2-52.

7. Schulman S, Kearon C, Kakkar AK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med, 2009 10 Dec, 361(24): 2342-2352.

8. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Hokusai-VTE Investigators, BЯller HR, DOcousus H. N Engl J Med, 2013 10 Oct, 369(15): 1406-1415.

9. Prins MH, Lensing AW, Bauersachs R. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J, 2013 Sep 20, 11(1): 21.

10. Agnelli G, Buller HR, Cohen A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013 Aug 29, 369(9): 799-808.

11. Otheino R, Abu Affan M, Okpo E. Home versus in-patient treatment of deep vein thombosis. Cochran Database Syst Rev, 2007, 3. CD003076.

12. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004, 126(3 Suppl): 401S-428S.

13. A randomized trial. Buller HR et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. Ann Intern Med, 2004, 140: 867-873.

14. Piran S, Le Gal G, Wells PS et al. Outpatient treatment of symptomatic pulmonary embolism: a systematic review and metaanalysis. Thromb Res, 2013, 132: 515-519.

15. Baglin T. Fifty per cent of patients with pulmonary embolism can be treated as outpatients. Thromb Haemost, 2010, 8: 2404-2405.

16. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model foe pulmonary embolism. Am J Respir Crit Care Med, 2005, 172(8): 1041.

17. Venetz C, JimOnez D, Mean M, Aujesky D et al. Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symp-tomatic Pulmonary Embolism. Arch Intern Med, 2010, 170(15): 1383-1389.

18. Trujillo-Santos J, Herrera S, Page MA, Soto MJ et al. Predicting adverse outcomes in outpatients with acute deep vein thrombosis. Findings from the RIETE registry. J Vasc Surg, 2006, 44: 789793.

19. Kearon C, Akl E, Comerota AJ et al. Antithrombotic therapy and prevention of thrombosis for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012, 141(2): e419S-e494s.

20. Winter M, Keelings D, Sharpen F et al. Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haematol, 2005, 27: 61-66.

21. Van der Hulle T, Kooiman J, den Exter PL et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost, 2014, 12: 320-328. doi:10.1111/jth.12485.

22. Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis, 2014. doi:10.1007/s11239-014-1102-5.

23. Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med, 2013, 368: 709-718.doi:10.1056/NEJMoa1113697.

24. EINSTEIN Investigators, Bauersachs R, Berkowitz SD et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010, 363: 2499-2510. doi:10.1056/NEJMoa1007903.

25. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368: 699-708. doi:10.1056/NEJMoa1207541.

26. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014, 129: 764-772. doi:10.1161/CIRCULATIONAHA.113.004450.

27. Buller HR, Prins MH et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. EINSTEIN-PE Investigators. N Engl J Med, 2012, 366: 1287-1297. doi:10.1056/NEJMoa1113572.

28. Maureen A. Smythe, Jennifer Priziola, Paul P. Dobesh, Diane Wirth, Adam Cuker, Ann K. Wittkowsky. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis, 2016, 41: 165-186.

29. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. Daniel M. Witt, Nathan P. Clark, Scott Kaatz, Terri Schnurr, Jack E. Ansell. 1, 2016 г., Journal of Thrombosis and Thrombolysis, Т. 41, стр. 187-205.

30. Turpie AGG et al. XALIA, a non-interventional study comparing rivaroxaban with standard anticoagulation for initial and long-term therapy in deep vein thrombosis: baseline demographics and hospitalization rates (PO607-TUE). International Society on Thrombosis and Haemostasis, 2015, 13(Suppl. 2): 1-997.

31. Ageno W., Mantovani L., Haas S. et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep vein thrombosis (XALIA): an international prospective non-interventional study. www.the-lancet.com/haematology. Published online December 7, 2015.


Для цитирования:


Стойко Ю.М., Карташева Е.Д. Выбор антикоагулянта у пациента с венозными тромбоэмболическими осложнениями. Стационарозамещающие технологии: Амбулаторная хирургия. 2016;(1-2):29-35.

For citation:


Stoyko Y.M., Kartasheva E.D. Choosing an anticoagulant for a patient with venous thromboembolic complications. Нospital-replacing technologies:Ambulatory surgery. 2016;(1-2):29-35. (In Russ.)

Просмотров: 66


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1477 (Print)
ISSN 2658-3542 (Online)